Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary) ; Cabergoline; Lanreotide; Octreotide
  • Indications Acromegaly
  • Focus Registrational; Therapeutic Use
  • Acronyms MPOWERED
  • Sponsors Chiasma

    • Most Recent Events

    • 18 Jun 2023 Results of Predictors of Response to Oral Octreotide Capsules in Patients With Acromegaly , presented at the 105th Annual Meeting of the Endocrine Society
    • 16 Jun 2023 Results assessing long-term efficacy and safety of OOC in patients with acromegaly who previously responded to and tolerated both OOC and injectable octreotide/lanreotide and completed the core phase, published in the Journal of Clinical Endocrinology and Metabolism
    • 05 Dec 2022 According to an Amryt Pharma media release, the European Commission (EC) approval of Mycapssa in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. The centralised marketing authorisation will be valid in all EU Member States as well as in Iceland, Liechtenstein, and Norway. The EC approval of Mycapssa is supported by efficacy and safety data from three Phase 3 studies including this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top